SBIR Phase II: Clinical-Scale Suspension Bioreactor for Primary Hematopoietic Culture
Tissue Therapeutics, Evanston IL
Investigators
Abstract
This Small Business Innovation Research Phase II project describes the development of a disposable, highly efficient suspension bioreactor for primary hematopoietic (blood cell-forming) cell culture. The unique challenges (heterogeneous nature, donor variability, and shear-sensitivity) of these cultures render traditional flask or suspension cultures unable to economically and consistently produce large quantities of cells. In Phase I, the feasibility and characteristics of a disposable suspension bioreactor was demonstrated. In Phase II, a scaled-up prototype of a large, agitated disposable bioreactor designed for clinical use (stem cell transplantation) will be constructed, characterized, and tested for reliability and durability. Gas and mass transfer correlations established in Phase I will be verified and extended. The use of medium optical density as a surrogate measure for cell density will be investigated. The final product will be a system that combines the simple, disposable nature of flask culture with the control and monitoring capabilities of a suspension bioreactor. The resulting system will enable the cost-effective production of large numbers of primary hematopoietic cells and will improve the effectiveness and decrease the cost of medical procedures in the fields of transplantation, immunotherapy, and gene therapy.
View original record on NSF Award Search →